FDA Panel Rejects MDMA for PTSD Treatment, Impacting Psychedelic Medicine
TL;DR
An FDA advisory committee has recommended against approving MDMA-assisted therapy for PTSD, citing insufficient evidence of its effectiveness and concerns over potential abuse and clinical trial misconduct. Despite promising results from Lykos Therapeutics' trials, the committee highlighted gaps in research data and the unregulated nature of the accompanying psychotherapy. The FDA will consider these recommendations in its final decision, which could significantly impact the future of psychedelic medicine.
- FDA panel reviews use of MDMA as a treatment for PTSD The Washington Post
- FDA Panel Rejects Use of MDMA for Treatment of PTSD The New York Times
- FDA Panel Votes Against MDMA As PTSD Treatment—A Potential Hitch For Drug's Approval Forbes
- The psychedelic medicine revolution just took a big loss POLITICO
- Psychedelics Are Challenging the Scientific Gold Standard The Atlantic
Want the full story? Read the original reporting
Read on The Washington Post